Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies

Simon, Tracey G., King, Lindsay Y., Chong, Dawn Q., Nguyen, Long H., Ma, Yanan, VoPham, Trang, Giovannucci, Edward L., Fuchs, Charles S., Meyerhardt, Jeffrey A., Corey, Kathleen E., Khalili, Hamed, Chung, Raymond T., Zhang, Xuehong, Chan, Andrew T.·2018·Hepatology
DOI 10.1002/hep.29660

Cited by (160)

Items 101–160 of 160

  1. Inverse association between type 2 diabetes and hepatocellular carcinoma in East Asian populations
    Jinlong Huo, Yaxuan Xu, Xingqi Chen, Jie Yu, Lijin Zhao · 2024 · Frontiers in Endocrinology
  2. Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats
    Norihisa Nishimura, Kosuke Kaji, Mitsuteru Kitade, Yosuke Aihara, Shinya Sato, Kenichiro Seki, Yasuhiko Sawada, Hiroaki Takaya, Yasushi Okura, Hideto Kawaratani et al. · 2018 · BMC Cancer
  3. Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study
    Maria Guarino, Giovan Giuseppe Di Costanzo, Dario Bruzzese, Anna Sessa, Marco Guarracino, Luca Rinaldi, Andrea Aglitti, Angelo Salomone Megna, Federica Morando, Nicola Coppola et al. · 2020 · Liver Cancer International
  4. Effects of Positive Hepatitis B Core Antibody and Metabolic Disorders in Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus
    Hae Lim Lee, Si Hyun Bae, Jaejun Lee, Pil Soo Sung, Sung Won Lee, Jeong Won Jang, Jung‐Min Lee, Jong Young Choi, Nam Ik Han, Seung Kew Yoon · 2021 · Cancer Control
  5. Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
    Camilo Julio Llamoza-Torres, María Fuentes-Pardo, Bruno Ramos‐Molina · 2024 · Metabolism and Target Organ Damage
  6. Association between diabetes mellitus and hepatocellular carcinoma
    Shih‐Wei Lai, Cheng‐Li Lin, Kuan‐Fu Liao · 2019 · European Journal of Gastroenterology & Hepatology
  7. Typ-2-Diabetes mellitus und gastrointestinale Krebsvorsorge
    Hans Scherübl · 2022 · Zeitschrift für Gastroenterologie
  8. Effects of visceral obesity on cytokine and hormonal regulation in patients with gastroesophageal reflux disease
    Yu.М. Stepanov, L.М. Mosiychuk, О.М. Tatarchuk, O.M. Shevtsova, О.П. Петішко · 2023 · GASTROENTEROLOGY
  9. Hot and Cold HCC: Uncoupling Viral Oncogenesis and Therapy
    Laura Sneller, Keshav Mathur, Shyam Kottilil, Poonam Mathur · 2025 · Viruses
  10. RNA splicing dysregulation in hepatocellular carcinoma: Molecular mechanisms, therapeutic targets, and intervention strategies—A comprehensive review
    Shuai Xiong, Lei Hu, Yun-Yang Sun, Wei Huang, Xiao-Yu Hu · 2026 · Biomedicine & Pharmacotherapy
  11. Mastering Core Recommendations during HEPAtology ROUNDS in Patients with Advanced Chronic Liver Disease
    Mauricio García-Saenz-de-Sicilia, Lolwa Al-Obaid, Dempsey L. Hughes, Andrés Duarte‐Rojo · 2022 · Seminars in Liver Disease
  12. Interplay Between Fatty Acids, Stearoyl-Co-A Desaturase, Mechanistic Target of Rapamycin, and Yes-Associated Protein/Transcriptional Coactivator With PDZ-Binding Motif in Promoting Hepatocellular Carcinoma
    Jihane N. Benhammou, Jim Sinnett-Smith, Joseph R. Pisegna, Enrique Rozengurt · 2022 · Gastro Hep Advances
  13. Metabolisches Syndrom und gastrointestinale Krebsvorsorge
    Hans Scherübl · 2022 · Zeitschrift für Gastroenterologie
  14. Residential mobility and liver cancer risk: findings from a prospective cohort study in Chinese women
    Jia‐Yi Tuo, Qiuming Shen, Zhuoying Li, Jing-Yu Benjamin Tan, Jie Fang, Lifeng Gao, Yuting Tan, Honglan Li, Yong‐Bing Xiang · 2024 · BMC Public Health
  15. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma
    Kelley M. Weinfurtner, Jennifer L. Dodge, Francis Y. Yao, Neil J. Mehta · 2020 · Transplantation Direct
  16. Insights into causal associations between type 2 diabetes and common human diseases: a phenotype-wide bi-directional Mendelian randomization analysis
    Wenxi Sun, Hongbao Cao, Dongming Liu, Ancha V. Baranova, Xiaobin Zhang, Fuquan Zhang · 2025 · Nutrition Metabolism and Cardiovascular Diseases
  17. Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathway for Type 2 diabetes pathogenesis
    Aron Park, Baeki E. Kang, Eun‐Ju Jin, Hyun Jin Kim, Chang-Woo Lee, Jae Myoung Suh, Dongryeol Ryu, Seungyoon Nam · 2025 · Genes & Genomics
  18. Clinical Impact and Therapeutic Management of Diabetes Mellitus in Patients With Decompensated Cirrhosis
    Chiara Lisi, Maria Laura Robone, M. Bonomo, Daniela Campion, Elisabetta Bugianesi, Carlo Alessandria · 2026 · Liver International
  19. Risk of Liver Cancer in MASLD: Role of Genetic Risk Scores
    Cláudia Maccali, Isabel Veloso Alves Pereira, José Tadeu Stefano, Claudia Pinto Marques Souza de Oliveira · 2023 · Current Hepatology Reports
  20. Severity of Complications and Duration of Type 2 Diabetes and the Risk of Cancer: A Population-Based Study
    Yu‐Wen Hu, Chiu‐Mei Yeh, Chia‐Jen Liu, Tzeng‐Ji Chen, Nicole Huang, Yiing‐Jenq Chou · 2024 · Cancer Epidemiology Biomarkers & Prevention
  21. Estimated Prevalence of Advanced Hepatic Fibrosis by Elastography in Patients with Type 2 Diabetes
    Yoshio Sumida · 2020 · Interventions in Obesity & Diabetes
  22. Global trends and thematic evolution of nursing in liver cancer: a bibliometric analysis of the web of science core collection (1944–2025)
    Yue Tian, Shun Li, Xiaoyan Zheng · 2026 · Discover Oncology
  23. Metabolic dysfunction profiles identify heterogeneous hepatocellular carcinoma risk in MASLD-associated advanced fibrosis
    Mario Romeo, Marcello Dallio, Carmine Napolitano, Fiammetta Di Nardo, Alessandro Federico · 2026 · Journal of Hepatology
  24. Diabetes und Gastroenterologie – Update 2017
    Jörg Bojunga, A. W. Mondorf · 2018 · Der Diabetologe
  25. The Role of Granzyme B Activity and Concentration, and Serpin B9 Concentration with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus
    Hussein S. Alshamary, Qasim Sharhan Al-Mayah, Fadhil Abdulla Abdul-Ridha · 2022 · Pakistan Journal of Medical and Health Sciences
  26. Krebsrisiko bei Prädiabetes und Typ-2-Diabetes mellitus
    Hans Scherübl · 2022 · Diabetologie und Stoffwechsel
  27. Preventing Hepatocellular Carcinoma: The Case for Childhood Intervention
    Sania Amr · 2018 · Journal of Pediatrics and Pediatric Medicine
  28. Changes in general and central fatness are associated with hepatocellular carcinoma: A Korean nationwide longitudinal study
    Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Seong Gyu Hwang · 2021 · International Journal of Cancer
  29. Association of type 2 diabetes with cancer: A meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people
    Suping Ling, Karen Brown, Joanne K. Miksza, Lynne M. Howells, Amy Morrison, Eyad Issa, Thomas E. Yates, Kamlesh K. Khunti, Melanie Jane Davies, Francesco Zaccardi · 2020
  30. Obesity and Hepatocarcinogenesis
    Y. Sumida, Yuya Seko, Tasuku Hara, A. Ohashi, Y. Nakade, Kiyoaki Ito, Haruhisa Nakao, Y. Fukuzawa, Y. Itoh, T. Okanoue et al. · 2019 · Alcoholic/Non-Alcoholic Digestive Diseases
  31. Diabetes in Liver Disease
    Takumi Kawaguchi, Dan Nakano, Takuji Torimura · 2019 · Springer eBooks
  32. Diabetes mellitus und Fettlebererkrankungen
    Jörg Bojunga, Andreas Geier · 2021 · Die Gastroenterologie
  33. Evaluating the Effect of Statins on Prognosis in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
    Hae Lim Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Nam Ik Han, Seung Kew Yoon, Ho Joong Choi, Gun Hyung Na, Young Kyoung You et al. · 2021 · Research Square
  34. Diabetes mellitus Typ 2 und Krebserkrankungen
    Christoph Steup, Jörg Trojan, Fabian Finkelmeier · 2021 · Der Diabetologe
  35. Research Status and Prospect of Metabolic Abnormalities in Hepatocellular Carcinoma
    峰 祁 · 2021 · Advances in Clinical Medicine
  36. Hepatocellular Carcinoma and Diabetes
    Sunanda Gupta, Manya Prasad, Archana Ramalingam · 2022 · Scholars Journal of Applied Medical Sciences
  37. Splenic artery ligation ameliorates postoperation liver function in HCC who underwent hepatectomy
    Dong Wang, Guo Long, Tongdi Fang, Ledu Zhou · 2022 · Research Square
  38. Typ-2-Diabetes mellitus und gastrointestinale Krebsvorsorge
    Hans Scherübl · 2022 · Diabetes aktuell
  39. A Cross-Sectional Study on Association between Metabolic Syndrome and Hepatobiliary Cancers
    Muhammad Irfan Shehzad, Anwar Ul Haq, Ikram Zada, Muhammad Adnan Shahid, Noman Kareem Qureshi, Shah Bakht Azeem · 2023 · Pakistan Journal of Medical and Health Sciences
  40. Data from Adiposity, Adulthood Weight Change, and Risk of Incident Hepatocellular Carcinoma
    Tracey G. Simon, Mi Na Kim, Xiao Luo, Xing Liu, Wanshui Yang, Yanan Ma, Dawn Qingqing Chong, Charles S. Fuchs, Meir J. Stampfer, Edward L. Giovannucci et al. · 2023
  41. Correlation between SREBP-1c and Prominent Nucleoli Hepatocytes of Type 2 Diabetic Rat Model Induced by Dietylnitrosamine
    Wahyuni L Atmadja, Erna Kristiani, Stella Marleen, Veli Sungono, Young Othiwi Larasati, Kevin Feraldy · 2023 · Journal Of Medicine & Health
  42. Progress in the Study of Risk Factors Associated with Primary Liver Cancer
    古门勒 乌日 · 2024 · Advances in Clinical Medicine
  43. High glucose stimulates liver cancer metastasis and invasion through the GFPT1/YAP/O-GlcNAcylation pathway
    Jiaojiao Guo, Chenyu Xie, Liangliang Ma, Zhizhong Guo, Congcong Zhang · 2025 · Research Square
  44. Highlighting the relevance of a multidisciplinary approach in metabolic-asociated steatotic liver disease (MASLD)
    Carmen Lara‐Romero, Miguel Angel Fernández-Gómez, Franz Martı́n, Luis Castilla‐Guerra, Jesús Funuyet‐Salas, Genoveva Berná, Raquel Millán-Domínguez, Manuel Romero‐Gómez · 2025 · Expert Review of Gastroenterology & Hepatology
  45. Burden and trends of NASH-related liver cancer associated with high fasting plasma glucose in China and globally from 1990 to 2021: a population-based analysis of the global burden of disease study
    Youjian Yao, Caifa Ji, Chenchen Zhou, Mei Gui · 2025 · BMJ Open
  46. Typ-2-Diabetes mellitus und gastrointestinale Krebsvorsorge
    Hans Scherübl · 2025 · Diabetologie und Stoffwechsel
  47. Additional file 2 of A global overview of genetically interpretable multimorbidities among common diseases in the UK Biobank
    Guiying Dong, Feng, Jianfeng, Fengzhu Sun, Chen, Jingqi, Zhao, Xing-Ming · 2021 · Figshare
  48. Additional file 1 of A global overview of genetically interpretable multimorbidities among common diseases in the UK Biobank
    Guiying Dong, Feng, Jianfeng, Fengzhu Sun, Chen, Jingqi, Zhao, Xing-Ming · 2021 · Figshare
  49. Additional file 1 of Low-density lipoprotein cholesterol and risk of hepatocellular carcinoma: a Mendelian randomization and mediation analysis
    Cao, Jiali, Ziwen Wang, Mengpei Zhu, Huang, Yumei, Ze Jin, Xiong, Zhifan · 2023 · Figshare
  50. Additional file 1 of Identification of metabolism genes related to hepatocarcinogenesis and progression in type 2 diabetes mellitus via co-expression networks analysis
    Bi, Yiming, Bei Yin, Fan, Guanjie · 2021 · Figshare
  51. Additional file 1 of Metabolic syndrome and its component traits present gender-specific association with liver cancer risk: a prospective cohort study
    Xia, Bin, Jianjun Peng, Enrico, De Toni, Lu, Kuiqing, Eddie C. Cheung, Kuo, Zichong, He, Qiangsheng, Yan Tang, Liu, Anran, Fan, Die et al. · 2021 · Figshare
  52. Metabolic burden-based clinical-radiological model for predicting postoperative recurrence of hepatitis B-related hepatocellular carcinoma
    Beixuan Zheng, Heqing Wang, Yuyao Xiao, Fei Wu, Chun Yang, Ruofan Sheng, Mengsu Zeng · 2026 · Insights into Imaging
  53. Income Persistence and the Risk of Hepatocellular Carcinoma in Individuals with Type 2 Diabetes
    Jong-Ha Baek, Yong-Moon Mark Park, Benjamin C. Amick, Mario Schootman, Michael R. Thomsen, Oak‐Kee Hong, Seung‐Hyun Ko, C Brown, Marie‐Rachelle Narcisse, Pearl A. McElfish et al. · 2026 · Cancer Epidemiology Biomarkers & Prevention
  54. Rising Cardiometabolic Comorbidity and Inpatient Resource Utilization Among Hospitalized Patients with Hepatocellular Carcinoma, 2018–2022
    Muhammad Haris Latif, Ayesha Kang, Eman Mazhar, Kahee A. Mohammed, Joel Riley, Hani-El Halawany, Kamran Qureshi · 2026 · Journal of Clinical Medicine
  55. Association between metabolic risk factors and hepatocellular carcinoma: a systematic review and meta-analysis of cohort studies
    Xiaoli Yang, Peng Fu, H L Liu · 2026 · Frontiers in Medicine
  56. GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma
    Alfredo Vozza, Filippo Biagi, Raggi Chiara, Francesco Vizzutti, Fabio Marra · 2026 · Internal and Emergency Medicine
  57. Hepatocellular Carcinoma Presenting With Extensive Portal Vein Tumour Thrombus Without Evidence of Underlying Liver Cirrhosis or Steatosis: A Case Report
    Ami Schattner, Livnat Uliel, Itzhak Schechtman, Ina Dubin · 2026 · British Journal of Hospital Medicine
  58. Disease burden and prediction of liver cancer attributable to metabolic risks in five East Asian countries from 1990 to 2023
    Jialu Wang, Huijiao Wang, Zixuan Huang, Xiling Liu, Dehua Wang, Huimin Yan · 2026 · PLoS ONE
  59. Dynamic Changes in Metabolic Syndrome and Risk of Hepatocellular Carcinoma: Evidence From a Nationwide Japanese Cohort
    Yutaka Yata, Naoki Kimoto, Yohei Miyashita, Takeshi Aketa, Takashi Washio, Kosuke Onoue, Masami Yabumoto, Sawako Uchida‐Kobayashi, Norifumi Kawada, Masafumi Kitakaze · 2026 · Liver international communications.
  60. Computational Design and Structure-Guided Optimization of Anti-Osteopontin Monoclonal Antibodies at the Intersection of Obesity, Type 2 Diabetes, and Hepatocellular Carcinoma
    Elahe Shams, Elham Rismani, Pedram Asadi Sarabi, Mohsen Nasiri‐Toosi, Reza Malekzadeh, Moustapha Hassan, Massoud Vosough · 2026 · Journal of Genome Biotechnology and Genetics